Vestmark Advisory Solutions Inc. Has $1.59 Million Position in Zoetis Inc. (NYSE:ZTS)

Vestmark Advisory Solutions Inc. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 56.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,784 shares of the company's stock after selling 12,769 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Zoetis were worth $1,594,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Mizuho Securities USA LLC grew its holdings in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after acquiring an additional 4,829,815 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Zoetis in the 4th quarter valued at $196,651,000. Assenagon Asset Management S.A. lifted its stake in shares of Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock valued at $144,917,000 after purchasing an additional 665,331 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock valued at $336,266,000 after purchasing an additional 572,511 shares during the last quarter. Finally, Holocene Advisors LP acquired a new stake in shares of Zoetis in the 3rd quarter valued at $110,809,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Remove Ads

Zoetis Stock Performance

Shares of ZTS traded up $3.09 during trading hours on Friday, reaching $170.34. 3,296,788 shares of the company traded hands, compared to its average volume of 3,274,650. The stock's fifty day moving average is $166.72 and its 200 day moving average is $176.78. The stock has a market cap of $76.28 billion, a P/E ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.17%. Zoetis's dividend payout ratio is 36.56%.

Analyst Ratings Changes

ZTS has been the subject of several analyst reports. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Finally, Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.